Exploration of various potential biomarkers to predict immunotherapy response in breast cancer, such as PD-L1 expression, TILs, microsatellite instability (MSI)/mismatch repair (MMR) defects, and TMB, is currently underway. This evidence concerns the gene CD274 and breast cancer.